SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Frédéric Chopin Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFrédéric Chopin
Date of birth1810-03-01
IdentifiersMRN HR-NI020-SYN-TD; SSN (made up) 000-20-8845
Document date2026-11-01
AuthorMatthias Lindqvist, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Three months of cough, two weeks of blood-streaked sputum, night sweats, and weight loss: chest X-ray and CT, sputum samples, blood tests, home airborne isolation, and a report of suspected tuberculosis to the health department. Concerns: He has coughed for about three months, now with streaks of blood, sweats at night, and has lost weight; he wants to know what is wrong; He teaches piano at home and performs; he wants to know when he can teach again and whether his students are at risk; He is afraid his students and neighbors will shun him if they learn he may have tuberculosis. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses)Oral route1838-03-20 to 1838-07-16completedS
Moxifloxacin 400 mg tablet, one tablet daily400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours afterOral route1838-03-20 to 1838-07-16completedS
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeksOral route1838-03-20 to 1838-07-16completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg)Oral route1838-03-20 to 1838-05-14completedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route1838-03-20 to 1838-07-16completedS

Procedures

ProcedureDatesStatusEvidence
Chest X-ray, two views: right upper lobe consolidation with a 2.5 cm thick-walled cavity and patchy opacities in the left upper zone; no effusion1838-03-17 to 1838-03-17completedS
CT of the chest without contrast: a 2.5 cm thick-walled cavity in the apical segment of the right upper lobe with surrounding consolidation and tree-in-bud nodules in both upper lobes; no bronchiectasis, no emphysema, no enlarged lymph nodes, no effusion1838-03-17 to 1838-03-17completedS
Chest X-ray, two views, at the end of treatment: cavity closed, with a small area of right upper lobe scarring; kept as the baseline for any future comparison1838-07-21 to 1838-07-21completedS

Immunizations

DateVaccineStatusEvidence
1835-10-04Tetanus, diphtheria, and pertussis (Tdap) boostercompletedS
1838-09-15Influenza vaccine, 1838-1839 seasoncompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1820sRecurrent episodes of cough, fever, headaches, and swollen lymph nodes in his teensD (CLM-0004)
winter of 1836 to 1837Serious illness; cause not recorded in the cited sourceD (CLM-0007)

Family History

RelativeConditionAge at deathEvidence
sisterTuberculosis; died of it in 1827D (CLM-0003)

Health Concerns

ConcernStatusEvidence
He has coughed for about three months, now with streaks of blood, sweats at night, and has lost weight; he wants to know what is wrongactiveS
He teaches piano at home and performs; he wants to know when he can teach again and whether his students are at riskactiveS
He is afraid his students and neighbors will shun him if they learn he may have tuberculosisactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 14.1 on 1838-07-21; Leukocytes [#/volume] in Blood by Automated count 9.6 on 1838-03-17; Platelets [#/volume] in Blood by Automated count 442 on 1838-03-17; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 1838-07-21; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 on 1838-05-15; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 1838-05-15; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 84 on 1838-03-17; Albumin [Mass/volume] in Serum or Plasma 4 on 1838-07-21; Creatinine [Mass/volume] in Serum or Plasma 0.78 on 1838-03-17; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1833)/1.73 sq M 125 on 1838-03-17; Glucose [Mass/volume] in Serum or Plasma 86 on 1838-03-17; Potassium [Moles/volume] in Serum or Plasma 4 on 1838-03-17; Calcium [Mass/volume] in Serum or Plasma 9 on 1838-03-17; Magnesium [Mass/volume] in Serum or Plasma 2 on 1838-03-17; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1838-07-21; Total score [AUDIT-C] 2 on 1838-09-15; Chloride [Moles/volume] in Sweat 18 on 1838-04-07; Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma by Nephelometry 142 on 1838-04-07; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1838-09-15 [S]

Strengths and supports: Born in Poland to a French father and a Polish mother; left home at 20 and has not been back; sources of support he names: a close circle of friends from home, his students, and his music [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and cultureresolvedconfirmed R04.2S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit.
Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic.
Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dLresolvedconfirmed E44.0S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion.
Acute viral upper respiratory infection during the continuation phase of tuberculosis treatment; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness chosen to teach how to tell a cold from tuberculosis treatment failure, and moxifloxacin interactions with cold remedies; it does not echo a documented illness.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1838-03-17Hemoglobin [Mass/volume] in Blood12.1g/dL13.2-16.6 g/dLLowS
1838-03-17Leukocytes [#/volume] in Blood by Automated count9.610*3/uL4-11 10*3/uLNormalS
1838-03-17Platelets [#/volume] in Blood by Automated count44210*3/uL150-400 10*3/uLHighS
1838-03-17Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-56 U/LNormalS
1838-03-17Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L10-40 U/LNormalS
1838-03-17Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
1838-03-17Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma84U/L40-129 U/LNormalS
1838-03-17Albumin [Mass/volume] in Serum or Plasma3.2g/dL3.5-5 g/dLLowS
1838-03-17Creatinine [Mass/volume] in Serum or Plasma0.78mg/dL0.74-1.35 mg/dLNormalS
1838-03-17Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1833)/1.73 sq M125mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1838-03-17Glucose [Mass/volume] in Serum or Plasma86mg/dL70-99 mg/dLNormalS
1838-03-17Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
1838-03-17Calcium [Mass/volume] in Serum or Plasma9mg/dL8.6-10.3 mg/dLNormalS
1838-03-17Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.7-2.2 mg/dLNormalS
1838-03-17Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1838-03-17Total score [AUDIT-C]2{score}S
1838-04-07Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma34U/L7-56 U/LNormalS
1838-04-07Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L10-40 U/LNormalS
1838-04-07Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.1-1.2 mg/dLNormalS
1838-04-07Chloride [Moles/volume] in Sweat18mmol/L<=29 mmol/LNormalS
1838-04-07Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma by Nephelometry142mg/dL100-190 mg/dLNormalS
1838-05-15Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L7-56 U/LNormalS
1838-05-15Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L10-40 U/LNormalS
1838-05-15Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1838-05-15Hemoglobin [Mass/volume] in Blood13g/dL13.2-16.6 g/dLLowS
1838-05-15Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1838-07-21Hemoglobin [Mass/volume] in Blood14.1g/dL13.2-16.6 g/dLNormalS
1838-07-21Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
1838-07-21Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-56 U/LNormalS
1838-07-21Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
1838-09-15Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1838-09-15Total score [AUDIT-C]2{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1838-03-17Body height170cmS
1838-03-17Body weight48.5kgS
1838-03-17Body mass index (BMI) [Ratio]16.8kg/m2S
1838-03-17Systolic blood pressure104mm[Hg]S
1838-03-17Diastolic blood pressure66mm[Hg]S
1838-03-17Heart rate102/minS
1838-03-17Respiratory rate20/minS
1838-03-17Body temperature37.9CelS
1838-03-17Oxygen saturation in Arterial blood by Pulse oximetry95%S
1838-03-20Body height170cmS
1838-03-20Body weight48.4kgS
1838-03-20Body mass index (BMI) [Ratio]16.7kg/m2S
1838-03-20Systolic blood pressure102mm[Hg]S
1838-03-20Diastolic blood pressure64mm[Hg]S
1838-03-20Heart rate98/minS
1838-03-20Respiratory rate18/minS
1838-03-20Body temperature37.6CelS
1838-03-20Oxygen saturation in Arterial blood by Pulse oximetry95%S
1838-04-07Body height170cmS
1838-04-07Body weight49.6kgS
1838-04-07Body mass index (BMI) [Ratio]17.2kg/m2S
1838-04-07Systolic blood pressure106mm[Hg]S
1838-04-07Diastolic blood pressure66mm[Hg]S
1838-04-07Heart rate86/minS
1838-04-07Respiratory rate16/minS
1838-04-07Body temperature37CelS
1838-04-07Oxygen saturation in Arterial blood by Pulse oximetry97%S
1838-05-15Body height170cmS
1838-05-15Body weight52kgS
1838-05-15Body mass index (BMI) [Ratio]18kg/m2S
1838-05-15Systolic blood pressure108mm[Hg]S
1838-05-15Diastolic blood pressure68mm[Hg]S
1838-05-15Heart rate78/minS
1838-05-15Respiratory rate16/minS
1838-05-15Body temperature36.8CelS
1838-05-15Oxygen saturation in Arterial blood by Pulse oximetry98%S
1838-07-21Body height170cmS
1838-07-21Body weight55kgS
1838-07-21Body mass index (BMI) [Ratio]19kg/m2S
1838-07-21Systolic blood pressure110mm[Hg]S
1838-07-21Diastolic blood pressure70mm[Hg]S
1838-07-21Heart rate72/minS
1838-07-21Respiratory rate14/minS
1838-07-21Body temperature36.6CelS
1838-07-21Oxygen saturation in Arterial blood by Pulse oximetry98%S
1838-06-09Body height170cmS
1838-06-09Body weight53.6kgS
1838-06-09Body mass index (BMI) [Ratio]18.5kg/m2S
1838-06-09Systolic blood pressure108mm[Hg]S
1838-06-09Diastolic blood pressure68mm[Hg]S
1838-06-09Heart rate88/minS
1838-06-09Respiratory rate16/minS
1838-06-09Body temperature37.6CelS
1838-06-09Oxygen saturation in Arterial blood by Pulse oximetry97%S
1838-09-15Body height170cmS
1838-09-15Body weight56.2kgS
1838-09-15Body mass index (BMI) [Ratio]19.4kg/m2S
1838-09-15Systolic blood pressure112mm[Hg]S
1838-09-15Diastolic blood pressure70mm[Hg]S
1838-09-15Heart rate70/minS
1838-09-15Respiratory rate14/minS
1838-09-15Body temperature36.6CelS
1838-09-15Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1838-03-17Three months of cough, two weeks of blood-streaked sputum, night sweats, and weight loss: chest X-ray and CT, sputum samples, blood tests, home airborne isolation, and a report of suspected tuberculosis to the health departmentfinishedS
1838-03-20Results visit: pulmonary tuberculosis confirmed; infectious diseases consultation and the start of the four-month rifapentine-moxifloxacin regimen by video-observed therapyfinishedS
1838-04-07Two-and-a-half-week review: release from isolation, return to teaching, liver tests, and tests for cystic fibrosis and alpha-1 antitrypsin deficiencyfinishedS
1838-05-15End of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phasefinishedS
1838-07-21End-of-treatment review after 119 dosesfinishedS
1838-06-09Same-day sick visit for a cold with cough during tuberculosis treatmentfinishedS
1838-09-15Adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Infectious diseases consultation to confirm the diagnosis, choose between the six-month and four-month regimens, plan monitoring and his return to teaching, and address cystic fibrosis and alpha-1 antitrypsin deficiency as explanations for his lifelong chest illnesscompletedGL-ATS-TB-2016, GL-CDC-4MO-2022S
Diagnosis: three sputum samples at least eight hours apart, one early in the morning, for acid-fast smear, nucleic acid amplification with rifampin resistance, culture, molecular testing for isoniazid and fluoroquinolone resistance, and phenotypic susceptibility; an interferon-gamma release assay; HIV, hepatitis B, and hepatitis C tests; and baseline blood count, liver and kidney tests, potassium, calcium, and magnesiumcompletedGL-ATS-TB-2016, GL-CDC-4MO-2022S
Infection control and public health: home airborne isolation with no students or visitors and a surgical mask around others; same-day report of suspected tuberculosis to the health department; a contact investigation of his students, friends, and other close contacts led by the health departmentcompletedGL-CDC-CONTACT-2005, GL-ATS-TB-2016S
Nutrition: two dietitian visits in the first month, three meals and three energy-dense snacks a day, two oral nutrition supplement drinks a day, and weight at every visitcompletedGL-ASPEN-MALN-2012, GL-ATS-TB-2016S
Support: plain information about how tuberculosis spreads, how quickly treatment makes him non-infectious, and that it is curable; help with what to tell his students; PHQ-9 at diagnosis, at two months, and at the end of treatmentcompletedGL-USPSTF-DEP-2023, GL-ATS-TB-2016S
Treatment: the four-month regimen of rifapentine 1200 mg, moxifloxacin 400 mg, isoniazid 300 mg, and pyrazinamide 1000 mg daily with food for eight weeks, then rifapentine, moxifloxacin, and isoniazid for nine weeks, with pyridoxine, by video-observed therapy seven days a week; complete when 119 doses are taken within five monthscompletedGL-CDC-4MO-2022, GL-ATS-TB-2025, GL-ATS-TB-2016S
Monitoring: symptoms, weight, adverse effects (liver, tendons, nerves) and observed doses at every visit; liver tests at two to three weeks and for symptoms; sputum smears in the third week for release, then monthly culture until two are negative, including the two-month culture; phenotypic susceptibility including moxifloxacin; PHQ-9 at two months and at the endcompletedGL-CDC-4MO-2022, GL-ATS-HEPATOTOX-2006S
Sweat chloride test and serum alpha-1 antitrypsin level once he is out of isolation, to address cystic fibrosis and alpha-1 antitrypsin deficiency as the proposed alternativescompletedGL-CFF-DX-2017, GL-ATS-A1AT-2003S

Goals

GoalTargetStatusOutcomeProvenance
Complete all 119 doses within five months by video-observed therapy1838-07-21completedAll 119 doses completed in 17 weeks: 56 in the intensive phase and 63 in the continuation phase, with none missedS
Sputum culture negative at two months1838-07-21completedThe two-month culture showed no growth, as did the cultures from the third weekS
Return to teaching once the health department confirms he is no longer infectious1838-04-07completedReleased from isolation after three negative smears and more than two weeks of treatment; teaching again from the third weekS
Weight back to at least 55 kg by the end of treatment1838-07-21completed55.0 kg at the end of treatment, from 48.5 kg at diagnosisS
PHQ-9 below 5 by the end of treatment1838-07-21completedPHQ-9 3 at the end of treatment, from 7 at diagnosisS

Functional Status

Mental Status